Atypical toxicity associated with 5-fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?

Journal of the Pancreas

Volumn 9, Issue 2, 2008, Pages 226-229

  Saif, Muhammad Wasif ^a   Seller, Sandra ^b   Diasio, Robert B ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Capecitabine; Exanthema; Fluorouracil

Indexed keywords

ANTIHISTAMINIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GEMCITABINE; STEROID; URIDINE DERIVATIVE;

AGED; ANEMIA; BODY RASH; CASE REPORT; DESQUAMATION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; ETHNICITY; FACE RASH; FEMALE; HAND RASH; HUMAN; LETTER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PERIORBITAL EDEMA; PHARMACOGENETICS; RISK ASSESSMENT; RISK FACTOR; SKIN TOXICITY; THROMBOCYTOPENIA;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG ERUPTIONS; FEMALE; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS;

EID: 42949164966     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Letter

References (17)

1. Lu Z, Zhang R, Carpenter JT. Diasio, RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer implication for 5-fluorouracil-based chemotherapy: Clin Cancer Res 1998; 4:325-9.
2. Lee A, Ezzeldin H, Fourie J, Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol 2004; 2:527-32.
3. Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 2006; 5:359-62.
4. Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B. Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancce. Magy Onkol 2007; 51:113-25.
5. Saif MW; Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? JOP. J Pancreas (Online) 2007; 8:799-805.
6. Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005; 23:8679-87.
7. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007; 43:1011-6.
8. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD·2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007; 60:503-7.
9. van Kuilenburg AB, Klumpen HJ, Westermann AM, Zoetekouw L, Van Lenthe H, Bakker PJ, et al. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer 2007; 43:459-65.
10. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renée N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12:2248-53.
11. Milano G, Etienne MC, Pierrefite V, Barberi Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79:627-30.
12. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12:5491-5
13. McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002; 9,4:1160-7.
14. Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi Y, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998; 4:2999-3004.
15. Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil ph J Cancer Res 2001; 92:337-42
16. Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehyorogenase deficiency in an Indian population. Cancer Chemother Pharmacol 2006; 58:396-401.
17. Liem LK,, Choong LH, Woo KT. Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay. Clini Biochem 2002; 35:181-7.